Comparing the current results to its competitors, Revelation Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.04 %, recorded in the same quarter.
Revelation Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 364.02 %
March 13, 2024
Revelation Biosciences Inc. is a clinical-stage life sciences company at the forefront of harnessing trained immunity for the prevention and treatment of diseases. Recently, they presented new preclinical data on the potential therapeutic benefit of their innovative product Gemini for the prevention of acute kidney injury (AKI) at the International Conference on Advances in Critical Care Nephrology (AKI and CRRT 2024) held in San Diego. With an invitation to deliver an oral presentation at The 29th International Conference on Advances in Critical Care Nephrology, Revelation Biosciences Inc. continues to make significant strides in the field of biotechnology.The Promise of Gemini:Gemini, developed by Revelati...
Publicly Traded Peers of Revelation Biosciences Inc
Abbvie Inc Share Performance
+17.48%
One Year
Abbvie Inc
Profile
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.
Greenwich Lifesciences Inc's business model focuses on the research, development, and commercialization of innovative therapies in the field of oncology.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Sources:
Revelation Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Revelation Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
